Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, et al.
OncoImmunology (2012) Vol. 1, Iss. 6, pp. 894-907
Open Access | Times Cited: 226

Showing 1-25 of 226 citing articles:

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jérôme Galon, Helen K. Angell, Davide Bedognetti, et al.
Immunity (2013) Vol. 39, Iss. 1, pp. 11-26
Open Access | Times Cited: 790
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp, Laura Senovilla, Ilio Vitale, et al.
OncoImmunology (2014) Vol. 3, Iss. 9, pp. e955691-e955691
Open Access | Times Cited: 755
Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis
Brittany D. Needham, M. Stephen Trent
Nature Reviews Microbiology (2013) Vol. 11, Iss. 7, pp. 467-481
Open Access | Times Cited: 489
Classification of current anticancer immunotherapies
Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, et al.
Oncotarget (2014) Vol. 5, Iss. 24, pp. 12472-12508
Open Access | Times Cited: 440
The Yin and Yang of Toll-like receptors in cancer
Jean‐Philippe Pradère, Dianne H. Dapito, Robert F. Schwabe
Oncogene (2013) Vol. 33, Iss. 27, pp. 3485-3495
Open Access | Times Cited: 305
Trial watch: IDO inhibitors in cancer therapy
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, et al.
OncoImmunology (2014) Vol. 3, Iss. 10, pp. e957994-e957994
Open Access | Times Cited: 288
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk, George J. Weiner
Cancer Research (2014) Vol. 75, Iss. 1, pp. 5-10
Open Access | Times Cited: 273
Trial watch
Erika Vacchelli, Laura Senovilla, Alexander Eggermont, et al.
OncoImmunology (2013) Vol. 2, Iss. 3, pp. e23510-e23510
Open Access | Times Cited: 264
Trial watch
Erika Vacchelli, Alexander Eggermont, Catherine Sautès‐Fridman, et al.
OncoImmunology (2013) Vol. 2, Iss. 6, pp. e24612-e24612
Open Access | Times Cited: 250
Trial watch
Erika Vacchelli, Ilio Vitale, Alexander Eggermont, et al.
OncoImmunology (2013) Vol. 2, Iss. 10, pp. e25771-e25771
Open Access | Times Cited: 244
Antitumour dendritic cell vaccination in a priming and boosting approach
Alexandre Harari, Michele Graciotti, Michal Bassani‐Sternberg, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 9, pp. 635-652
Closed Access | Times Cited: 225
Trial watch: TLR3 agonists in cancer therapy
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 224
Trial watch
Laura Senovilla, Erika Vacchelli, Jérôme Galon, et al.
OncoImmunology (2012) Vol. 1, Iss. 8, pp. 1323-1343
Open Access | Times Cited: 221
A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
Qianqian Ni, Fuwu Zhang, Yijing Liu, et al.
Science Advances (2020) Vol. 6, Iss. 12
Open Access | Times Cited: 215
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Marina Luchner, Sören Reinke, Anita Milicic
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 142-142
Open Access | Times Cited: 212
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Melody Smith, Elena García-Martínez, Michael Pitter, et al.
OncoImmunology (2018) Vol. 7, Iss. 12, pp. e1526250-e1526250
Open Access | Times Cited: 200
Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy
Yuanyuan Liu, Linan Qiao, Sipei Zhang, et al.
Acta Biomaterialia (2017) Vol. 66, pp. 310-324
Closed Access | Times Cited: 188
Enhancing in situ cancer vaccines using delivery technologies
Ningqiang Gong, Mohamad‐Gabriel Alameh, Rakan El‐Mayta, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 8, pp. 607-625
Closed Access | Times Cited: 28
Clinical landscape of macrophage-reprogramming cancer immunotherapies
Jenna H. Rannikko, Maija Hollmén
British Journal of Cancer (2024) Vol. 131, Iss. 4, pp. 627-640
Open Access | Times Cited: 17
Trial watch
Erika Vacchelli, Isabelle Martins, Alexander Eggermont, et al.
OncoImmunology (2012) Vol. 1, Iss. 9, pp. 1557-1576
Open Access | Times Cited: 169
Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Huju Chi, Chunman Li, Flora Sha Zhao, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 162
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
James Q. Wang, Yogesh Jeelall, Laura L. Ferguson, et al.
Frontiers in Immunology (2014) Vol. 5
Open Access | Times Cited: 154
Trial Watch: Monoclonal antibodies in cancer therapy
Lorenzo Galluzzi, Erika Vacchelli, Wolf H. Fridman, et al.
OncoImmunology (2012) Vol. 1, Iss. 1, pp. 28-37
Open Access | Times Cited: 148
Trial watch
Lorenzo Galluzzi, Laura Senovilla, Erika Vacchelli, et al.
OncoImmunology (2012) Vol. 1, Iss. 7, pp. 1111-1134
Open Access | Times Cited: 148
Trial Watch
Erika Vacchelli, Alexander Eggermont, Catherine Sautès‐Fridman, et al.
OncoImmunology (2013) Vol. 2, Iss. 8, pp. e25238-e25238
Open Access | Times Cited: 147
Page 1 - Next Page

Scroll to top